首页> 外文学位 >Genetic engineering of cardiac progenitor cells for the treatment of cardiovascular disease and heart failure.
【24h】

Genetic engineering of cardiac progenitor cells for the treatment of cardiovascular disease and heart failure.

机译:心脏祖细胞的基因工程,用于治疗心血管疾病和心力衰竭。

获取原文
获取原文并翻译 | 示例

摘要

Cardiovascular disease (CVD) afflicts an estimated one in three people in the United States, accounting for more deaths annually than all other causes of death combined. The most prevalent form of CVD is coronary artery disease (CAD). CAD often leads to myocardial infarction (MI) with subsequent death of the underlying cardiac tissue. While current pharmaceutical treatments help to alleviate the increased demands placed on the damaged heart, they do nothing to regenerate and repair damaged tissue.;Recently, the use of stem cells to regenerate cardiac tissue is being explored. Unfortunately, only modest improvements in myocardial function after stem cell transplantation have been observed, raising concerns over the retention and viability of transplanted stem cells once in the damaged heart. To this end, the field of cardiac regeneration is evolving to include genetic manipulation of stem cells using cardioprotective genes to increase survival and proliferation in vivo.;Herein, we evaluate the ability of cardiac progenitor cells (CPC), genetically modified with the known cardioprotective genes, nuclear-targeted Akt or Pim-1, to improve cardiac structure and function after infarction in mice. The results presented in this thesis demonstrate CPCs modified with either nuclear Akt or Pim-1 significantly enhance proliferation in vitro and in vivo. However, overexpression of nuclear Akt in CPCs abrogates lineage commitment. Lack of terminal differentiation resulted in a lack of significant functional and structural improvements in the hearts of mice receiving injections after MI. In contrast, CPCs modified with Pim-1 kinase exhibited lineage commitment in vitro and in vivo. Mice receiving Pim-1 modified CPCs after infarction, therefore, had significant improvements in cardiac function and regeneration, compared to mice receiving unmodified CPCs. Preliminary studies indicate cellular localization of Pim-1 kinase may contribute to its ability to regulate stem cell proliferation and survival.;Taken together, this study demonstrates that CPC commitment is an essential component of the regenerative response. For cardiac stem cell therapies to be effective, cellular survival and proliferation must be promoted without inhibiting lineage commitment.
机译:在美国,估计有三分之一的人患有心血管疾病(CVD),每年造成的死亡人数超过所有其他死因之和。 CVD的最普遍形式是冠状动脉疾病(CAD)。 CAD通常会导致心肌梗塞(MI),并随后导致基础心脏组织死亡。尽管当前的药物治疗有助于减轻对受损心脏的需求,但它们对再生和修复受损组织无能为力。最近,正在探索使用干细胞再生心脏组织。不幸的是,仅观察到干细胞移植后心肌功能的适度改善,这引发了人们对一旦移植的干细胞一旦进入受损心脏的保留和生存能力的担忧。为此,心脏再生领域正在发展,包括使用心脏保护性基因对干细胞进行基因操作以增加体内存活和增殖。在此,我们评估了用已知的心脏保护性基因进行修饰的心脏祖细胞(CPC)的能力。核靶向的Akt或Pim-1基因可改善小鼠梗死后的心脏结构和功能。本文提出的结果表明,用核Akt或Pim-1修饰的CPCs可以显着增强体外和体内的增殖。但是,在CPC中过分表达核Akt废除了沿袭承诺。缺乏终末分化导致MI后接受注射的小鼠心脏缺乏明显的功能和结构改善。相反,用Pim-1激酶修饰的CPC在体外和体内均显示出谱系承诺。因此,与接受未经修饰的CPC的小鼠相比,梗死后接受Pim-1修饰的CPC的小鼠的心脏功能和再生能力显着改善。初步研究表明Pim-1激酶的细胞定位可能有助于其调节干细胞增殖和存活的能力。总而言之,这项研究表明CPC承诺是再生反应的重要组成部分。为了使心脏干细胞疗法有效,必须在不抑制谱系承诺的情况下促进细胞存活和增殖。

著录项

  • 作者

    Fischer, Kimberlee Marie.;

  • 作者单位

    University of California, San Diego and San Diego State University.;

  • 授予单位 University of California, San Diego and San Diego State University.;
  • 学科 Biology Molecular.;Biology Cell.
  • 学位 Ph.D.
  • 年度 2010
  • 页码 153 p.
  • 总页数 153
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 人口学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号